Literature DB >> 22258493

Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis.

Adelheid Korb-Pap1, Athanasios Stratis, Katja Mühlenberg, Birgit Niederreiter, Silvia Hayer, Frank Echtermeyer, Richard Stange, Jochen Zwerina, Thomas Pap, Hermann Pavenstädt, Georg Schett, Josef S Smolen, Kurt Redlich.   

Abstract

OBJECTIVE: To elucidate the mechanisms involved in cartilage damage in an experimental model of rheumatoid arthritis (RA) by specifically addressing the time course of extracellular matrix degradation and the contribution of cell-matrix interactions for initiation and perpetuation of this process.
METHODS: The human tumour necrosis factor (TNF) transgenic (hTNFtg) mouse model of RA was used to analyse the time course of pannus attachment to the cartilage and cartilage destruction, respectively, and crossed hTNFtg mice with interleukin (IL)-1(-/-) animals were used to investigate the role of IL-1 on these TNF-induced mechanisms in vivo. In addition, an in vitro attachment assay using synovial fibroblasts (SFs) from hTNFtg mice and freshly isolated articular cartilage was used to determine the role of proteoglycan loss in attachment of SFs and the role of the transmembrane heparan sulfate proteoglycan syndecan-4.
RESULTS: In vivo analyses of hTNFtg mice showed that proteoglycan loss induced by IL-1 precedes and constitutes an important prerequisite for these processes as, in hTNFtg mice, IL-1 deficiency protected from the loss of cartilage proteoglycans and almost completely prevented the attachment and subsequent invasion of inflamed synovial tissue into cartilage. In vitro studies confirmed that loss of cartilage proteoglycans is required for attachment of SFs and that syndecan-4 is prominently involved in SF attachment and activation.
CONCLUSIONS: The results of this study suggest that the loss of cartilage proteoglycans is an early event in the course of destructive arthritis that facilitates the attachment of the inflamed synovial membrane and also initiates matrix degradation and inflammation through cell-matrix interactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258493     DOI: 10.1136/annrheumdis-2011-200386

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  35 in total

Review 1.  Syndecans in chronic inflammatory and autoimmune diseases: Pathological insights and therapeutic opportunities.

Authors:  Solomon A Agere; Eugene Y Kim; Nahid Akhtar; Salahuddin Ahmed
Journal:  J Cell Physiol       Date:  2018-03-25       Impact factor: 6.384

Review 2.  Damage-associated molecular patterns in the pathogenesis of osteoarthritis: potentially novel therapeutic targets.

Authors:  John H Rosenberg; Vikrant Rai; Matthew F Dilisio; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2017-05-04       Impact factor: 3.396

Review 3.  Cartilage damage in osteoarthritis and rheumatoid arthritis--two unequal siblings.

Authors:  Thomas Pap; Adelheid Korb-Pap
Journal:  Nat Rev Rheumatol       Date:  2015-07-21       Impact factor: 20.543

Review 4.  Syndecans in cartilage breakdown and synovial inflammation.

Authors:  Thomas Pap; Jessica Bertrand
Journal:  Nat Rev Rheumatol       Date:  2012-10-23       Impact factor: 20.543

Review 5.  Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis.

Authors:  William P Arend; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2012-08-21       Impact factor: 20.543

Review 6.  Mechanisms of tissue damage in arthritis.

Authors:  Stephan Blüml; Kurt Redlich; Josef S Smolen
Journal:  Semin Immunopathol       Date:  2014-09-12       Impact factor: 9.623

7.  Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice.

Authors:  Berno Dankbar; Michelle Fennen; Daniela Brunert; Silvia Hayer; Svetlana Frank; Corinna Wehmeyer; Denise Beckmann; Peter Paruzel; Jessica Bertrand; Kurt Redlich; Christina Koers-Wunrau; Athanasios Stratis; Adelheid Korb-Pap; Thomas Pap
Journal:  Nat Med       Date:  2015-08-03       Impact factor: 53.440

8.  Autoinhibitory regulation of S100A8/S100A9 alarmin activity locally restricts sterile inflammation.

Authors:  Thomas Vogl; Athanasios Stratis; Viktor Wixler; Tom Völler; Sumita Thurainayagam; Selina K Jorch; Stefanie Zenker; Alena Dreiling; Deblina Chakraborty; Mareike Fröhling; Peter Paruzel; Corinna Wehmeyer; Sven Hermann; Olympia Papantonopoulou; Christiane Geyer; Karin Loser; Michael Schäfers; Stephan Ludwig; Monika Stoll; Tomas Leanderson; Joachim L Schultze; Simone König; Thomas Pap; Johannes Roth
Journal:  J Clin Invest       Date:  2018-04-03       Impact factor: 14.808

9.  Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy.

Authors:  Karen M Doody; Stephanie M Stanford; Cristiano Sacchetti; Mattias N D Svensson; Charlotte H Coles; Nikolaos Mitakidis; William B Kiosses; Beatrix Bartok; Camille Fos; Esther Cory; Robert L Sah; Ru Liu-Bryan; David L Boyle; Heather A Arnett; Tomas Mustelin; Maripat Corr; Jeffrey D Esko; Michel L Tremblay; Gary S Firestein; A Radu Aricescu; Nunzio Bottini
Journal:  Sci Transl Med       Date:  2015-05-20       Impact factor: 17.956

10.  Therapeutic effect of various ginsenosides on rheumatoid arthritis.

Authors:  Meng Zhang; Hongwei Ren; Kun Li; Shengsheng Xie; Ru Zhang; Longlong Zhang; Jiaxuan Xia; Xing Chen; Xilin Li; Jianxin Wang
Journal:  BMC Complement Med Ther       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.